Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call Transcript

So that’s where a lot of our focus is. And opportunistically, we have some meaningful data, some scientific breakthroughs, if you will, we will disclose those. Right now, I’ve said — I think I’ll make more comments available externally once we have a clear path to commercialization within the 12 to 24-month timeline. And right now, our current R&D pipeline doesn’t have projects which fit that. But that doesn’t mean that the current projects can’t fall into that over time. I just need to gain a level of certainty and derisk in some of the — either whether it be technical performance of the assay or in the reimbursement side before commenting on them. So that’s kind of the conservatism we’ve taken in detailing our R&D pipeline. Hopefully, that helps, Ross.

Ross Osborn: Thanks for the update. Congrats again on the quarter.

John Aballi: Thanks.

Operator: Thank you. There are no further questions at this time. I would now like to turn the floor back over to John Aballi for closing comments.

John Aballi: Great. Q2 was another strong quarter where we continue to execute on our objectives and in pursuit of a profitable organization. We’re making great progress. And I’m especially proud of the Exagen team for navigating these changes effectively through this point. Thank you for your interest in Exagen. And we look forward to continuing to provide updates on our progress as we work to improve our organization. Thank you.

Operator: Thank you. This does conclude today’s teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.